Article · Volume 57, Issue 3S · pp. s701–s709

Brassinin Exhibits Anti-Diabetic Activity against Streptozotocin-induced Diabetes Mellitus in Experimental Rats

Bixia Xu¹, Abdullah A. Alarfaj², Abdurahman Hajinur Hirad², Nandakumar Natarajan³, Petchi Iyappan⁴, Samer Hasan Hussein Al Ali⁵

¹Teaching and Research Section of Internal Medicine, Zhaoqing Medical College, Guangdong Province, CHINA.
²Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, SAUDI ARABIA.
³Department of Cellular and Molecular Biology, University of Texas at Tyler Health Science Center, Tyler, TEXAS, USA.
⁴Faculty of Medicine, Bioscience and Nursing, Mahsa University, Saujana Putra, MALAYSIA.
⁵Department of Chemistry, Faculty of Science, Isra University, Amman, JORDAN.

Abstract

Background: Diabetes mellitus is among the most serious public health problems worldwide.Materials and Methods: 35mg/kg STZ was injected to rats for stimulating diabetes. Then rats were treated with 25mg/kg of brassinin.Results: Brassinin and Glibenclamide remarkably decreased glucose and HbA1c levels in diabetic rats, while insulin levels were elevated. They also increased antioxidant enzymes and decreased inflammatory markers.Conclusion: Brassinin is an antihyperglycemic, antioxidant, and anti-inflammatory compound that protects the liver, kidney, and pancreas during diabetes.

Keywords: Brassinin; Glycosylated haemoglobin; Oxidative stress; Inflammation

The full text of this article is available as a PDF. Open the PDF.